Comparison of fesoterodine and mirabegron in the treatment of female overactive baldder patients with urgency incontinence: A randomized, prospective study (Feminine study)
Phase 4
- Conditions
- overactive bladder
- Registration Number
- JPRN-UMIN000024442
- Lead Sponsor
- Department of urology, Nagoya University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- Female
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
Patients were excluded if they received oral anticholinergic agents, alpha1-blockers, antidepressants, or anti-anxiety agents, had obvious neurogenic bladder dysfunction, bladder calculi, or active urinary tract infection, or had severe cardiac disease, renal dysfunction (serum-creatinine >2 mg/dL), and/or hepatic dysfunction (i.e., aspartate aminotransferase and alanine aminotransferase levels of more than twice the normal value)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method the change of urgency incontinence between fesoterodine and mirabegron
- Secondary Outcome Measures
Name Time Method the change of CLSS, OABSS, OAB-q, and ICIQ-SF